{
    "nct_id": "NCT06693284",
    "official_title": "A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",
    "inclusion_criteria": "* Known Neurofibromatosis type 1 (NF-1) syndrome based on current diagnostic criteria.\n* Diagnosis of suspected MPNST by PET or MRI imaging\n* Confirmation of histone H3 lysine 27 trimethylation-negative MPSNT by immunohistochemistry\n* Twelve years of age or older\n* Complete blood count (CBC), platelet, liver and kidney function within institutional normal limits performed within 14 days of 1 st dose of study drug.\n* Must be able to swallow capsules.\n* Females of childbearing potential must use highly effective contraception (see inclusion criteria section) from the time of study enrollment through 6 months after the last dose of vorinostat and mirdametinib. Males with partners of childbearing potential must use highly effective contraception from the time of study enrollment through 3 months after the last dose of vorinostat.\n* Provides voluntary written consent prior to any study related activities, with parental/guardian consent and assent for those 12 to 17 years of age at enrollment.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding - females of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to the 1 st dose of the study drugs.\n* Significant cardiac disease\n* Significant eye disease\n* Radiation therapy or chemotherapy in the past year.",
    "miscellaneous_criteria": ""
}